Bodine Journal

Article Title

Toxicity of Phase I Radiation Oncology Trials: Worldwide Experience

Authors

C. Glass, Jefferson Medical College
R. B. Den, Thomas Jefferson University and HospitalsFollow
A. P. Dicker, Thomas Jefferson University and HospitalsFollow
Y. R. Lawrence, Thomas Jefferson University and Hospitals

Abstract

Introduction: Informed consent involves understanding the risks and benefits of trial enrollment. This is challenging in the phase I setting since true quantitative information is never known. We therefore performed an analysis of published radiation oncology (RO) phase I trials emphasizing patient outcomes. To our knowledge, no such systemic analysis has previously been published.

American Society for Therapeutic Radiation Oncology (ASTRO) 52nd Annual Meeting October 31 - November 4, San Diego, CA

Recommended Citation

Glass, C.; Den, R. B.; Dicker, A. P.; and Lawrence, Y. R. (2010) "Toxicity of Phase I Radiation Oncology Trials: Worldwide Experience," Bodine Journal: Vol. 3: Iss. 1, Article 31.
DOI: https://doi.org/10.29046/TBJ.003.1.030
Available at: https://jdc.jefferson.edu/bodinejournal/vol3/iss1/31